Understanding factors associated with vaccine uptake and vaccine hesitancy in patients with rheumatoid arthritis: a scoping literature review

Boucher, Vincent Gosselin; Peláez, Sandra; Gemme, Claudia; Labbé, Sara; Lavoie, Kim

doi:10.1007/s10067-020-05059-7

Cited by 33 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Influenza vaccination has been previously studied in other chronic inflammatory diseases such as rheumatoid arthritis. A recent review on 16 studies found influenza vaccination rates ranging from 25.3 to 93.0% (mean: 59.5%), which is considerably higher than in our cohort [ 15 ].…”

Section: Discussioncontrasting

confidence: 60%

“…Although diagnosis of PsO alone is currently not explicitly mentioned as an indication for influenza vaccination by the RKI [ 6 , 13 , 14 ], there are a considerable number of PsO patients who are—irrespective of their age—at increased risk for serious infection due to systemic immunosuppressive or immunomodulatory medication or the above-mentioned comorbidity, and thus should receive yearly influenza vaccinations, following the RKI recommendations [ 6 , 13 , 14 ]. Influenza vaccination has been studied in other chronic inflammatory diseases such as rheumatoid arthritis [ 15 ]. However, there is limited evidence on actual vaccination rates in psoriatic patients in Germany [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influenza Vaccination in Psoriatic Patients—Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)

et al. 2021

View full text Add to dashboard Cite

The risk of developing severe complications from an influenza virus infection is increased in patients with chronic inflammatory diseases such as psoriasis (PsO) and atopic dermatitis (AD). However, low influenza vaccination rates have been reported. The aim of this study was to determine vaccination rates in PsO compared to AD patients and explore patient perceptions of vaccination. A multicenter cross-sectional study was performed in 327 and 98 adult patients with PsO and AD, respectively. Data on vaccination, patient and disease characteristics, comorbidity, and patient perceptions was collected with a questionnaire. Medical records and vaccination certificates were reviewed. A total of 49.8% of PsO and 32.7% of AD patients were vaccinated at some point, while in season 2018/2019, 30.9% and 13.3% received an influenza vaccination, respectively. There were 96.6% and 77.6% of PsO and AD patients who had an indication for influenza vaccination due to age, immunosuppressive therapy, comorbidity, occupation, and/or pregnancy. Multivariate regression analysis revealed higher age (p < 0.001) and a history of bronchitis (p = 0.023) as significant predictors of influenza vaccination in PsO patients. Considering that most patients had an indication for influenza vaccination, the rate of vaccinated patients was inadequately low.

show abstract

Section: Discussioncontrasting

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Influenza Vaccination in Psoriatic Patients—Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This issue can also be of great interest among other professionals who also deal with chronic autoimmune diseases, such as rheumatologists. 21 , 22 Throughout the short follow-up period, 10 pwMS were infected by SARS-CoV-2 between the first and second vaccine dose, all of them with a mild or asymptomatic disease. Recent publications showed that anti-CD20 treatment and fingolimod led to a reduced humoral response to mRNA-based SARS-CoV-2 vaccines in pwMS.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America

Alonso

Chertcoff²,

Leguizamón

et al. 2021

Multiple Sclerosis Journal - Experimental, Translational and Cl

View full text Add to dashboard Cite

Background To date, there are no data available on the safety of COVID-19 vaccines in Latin American patients with Multiple Sclerosis (MS). Objective Characterize safety of COVID-19 vaccines in Latin American (LATAM) patients with Multiple Sclerosis (pwMS). Methods A cross-sectional study between February 1, 2021, and April 30, 2021. Individuals with MS from LATAM countries were invited to participate in a self-administered web-based survey, through MS patient organizations from the region. Results 393 vaccinated pwMS from 10 different Latin American countries were included. The vaccines administered were: inactivated virus vaccines (IVV) in 38.2% of patients, adenovirus vector vaccines (AdV) in 48.8% and mRNA vaccines 13%. All patients received at least one dose of any of the COVID-19 vaccines and 123 (31.3%) declared receiving a second dose. Mean (SD) age 41.5 (11.8) years, 82.4% female, MS disease duration: 8.4 (8.2) years. No serious adverse events were reported with any of the COVID-19 vaccines after either the first or second dose. A lower frequency of adverse events was found with IVV (22%) in comparison with AdV (46.4%) and mRNA (35.3%) ( p < 0.01). Five participants reported having an MS relapse after IVV first dose. Conclusion COVID-19 vaccines applied in LATAM proved safe for MS patients.

show abstract

“…For this study, one independent rater skilled in MC and blind to the research objectives and physician training status (pre or post) rated physician performance on each of the MITI competencies during a 5-10-min audio-taped role-play exercise between the physician and a standardized patient who was vaccine hesitant. This patient used a script informed by a literature review on the determinants of influenza vaccine hesitancy in this population [30].…”

Section: Competency With a Standardized Patientmentioning

confidence: 99%

Training Physicians in Motivational Communication to Address Influenza Vaccine Hesitation: A Proof-of-Concept Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Strategies to support health care professionals on how to address vaccine hesitancy are needed. Methods: We developed a 4-h Motivational Communication (MC) training program tailored to help physicians address hesitancy related to influenza vaccination among patients living with rheumatoid arthritis. Five MC competencies were evaluated at baseline and post-training with a standardized patient using the Motivational Interviewing Treatment Integrity [MITI] scale. Adherence to MC during clinical consultations and changes in vaccine intentions was measured as secondary outcomes. Results: Seven rheumatology physicians participated in the training. MITI scores increased in all participants, and 71% (n = 5) achieved thresholds of clinical competency (i.e., ≥3.5/5 at MITI global score and ≥3/5 on at least 3 individual competency score) post-training. Autonomy/support and empathy competencies reached competency thresholds (+2.4 ± 1.3 to +4.1 ± 0.7 and +2.1 ± 0.7 to +4.1 ± 0.7, respectively). Evocation and collaboration competencies improved but without reaching competency thresholds (+1.4 ± 0.8 to +3.1 ± 1.1; +1.4 ± 0.8 to +2.9 ± 1.1, respectively). Direction did not improve. Among 21 patient consultations post-training, 15 (71%) were MC-consistent. Of the 15 patients, 67% (10/15) intended to receive the influenza vaccine and 33% (5/15) received it. Conclusion: A brief MC training program targeting vaccine hesitancy increased MC competency among rheumatology physicians and promoted behavioral change among patients.

show abstract

Understanding factors associated with vaccine uptake and vaccine hesitancy in patients with rheumatoid arthritis: a scoping literature review

Cited by 33 publications

References 42 publications

Influenza Vaccination in Psoriatic Patients—Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)

Influenza Vaccination in Psoriatic Patients—Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)

Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America

Training Physicians in Motivational Communication to Address Influenza Vaccine Hesitation: A Proof-of-Concept Study

Contact Info

Product

Resources

About